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osting by EAbstract Recent ﬁndings of acrylamide (AA) in many common foods have sparked renewed inter-
est in assessing human health hazards. AA was evaluated by the International Agency for Research
on Cancer as probably carcinogenic to humans. For this reason, the aim of this study is to evaluate
the potential genotoxic effect of AA using chromosomal aberration analysis and micronucleus
(MN) test in mouse bone-marrow cells and morphological sperm abnormalities. The result of the
present work indicated that treatment with a single dose of 10, 20, or 30 mg/kg b.wt. of AA for
24 h and the repeated dose of 10 mg/kg b.wt. for 1and 2 weeks induced a statistically signiﬁcant
increase in the percentage of chromosomal aberrations and micronuclei in bone- marrow cells.
These percentages reduced signiﬁcantly in all groups treated with AA and the protective agent L-
carnitine. Also the results indicated that the dose 10, 20 and 30 mg/kg b.wt. of AA induced a sta-
tistically signiﬁcant percentage of morphological sperm abnormalities compared with the control
group. Such effect reached its maximum (7.24 ± 0.61) with the highest tested dose which reduced
to (4.02 ± 0.58) in the group treated with the same dose of AA and L-carnitine. In conclusion, the
results conﬁrm the protective role of LC against the mutagenicity of AA.
ª 2010 King Saud University. All rights reserved.1. Introduction
Acrylamide (AA) is a high-production vinyl compound whose
polymeric form is used in the construction and oil industry, in698421817.
ity. All rights reserved. Peer-
d University.
lsevierthe manufacture of paper, plastics and textiles, as a ﬂocculant
in the treatment of waste water, and in cosmetics (Friedman,
2003). A worldwide public concern has been caused by the
ﬁnding that the same compound is generated in many common
foods during cooking at high temperatures (Svensson et al.,
2003). For example, AA reaches parts per million concentra-
tions in French fries, potato and tortilla chips, bread crust,
various baked foods, breakfast cereals and coffee. Further
studies showed that AA is formed during the Maillard brown-
ing reaction from a heat-induced reaction between the amino
acid asparagine and the carbonyl group of glucose (Stadler
et al., 2002).
With respect to the AA genotoxicity data, AA has been
shown to be clastogenic and mutagenic in rodents in vivo
30 H.A.S. Alzahrani(Dearﬁeld et al., 1995). AA could induce DNA damage in the
PC Cl3 and FRTL5 rat thyroid cell lines, as well as in human
lymphoblastoid TK6 cells in the Comet assay (Koyama et al.,
2006). Additionally, the results presented recently by Park
et al. (2002) suggested that AA itself appears to be involved
in AA-induced cellular transformation and that cellular thiol
status is involved in AA morphological transformation. AA
decreased glutathione (GSH) levels in Syrian hamster embryo
(SHE) cells (Park et al., 2002). It has also been found to be
conjugated with GSH (Tong et al., 2004). It is possible that
AA itself can be cytotoxic and genotoxic by decreasing the oxi-
dative defense system in the cells (Zamorano-Ponce et al.,
2006), as well as, releasing the reactive oxygen species (ROS)
(Liping et al., 2007). However, AA itself reacts quite slowly
with DNA (Solomon et al., 1985). Within the cells AA can
be oxidized to the more reactive glycidamide (GA) by cyto-
chrome P450-depended monooxygenase (CYP2E1) (Sumner
et al., 1999). GA has been reported to be 100–1000 times more
reactive with DNA than AA (Segerback et al., 1995). GA is
known to be clastogenic and mutagenic in vitro and in vivo
(Paulsson et al., 2003; da Costa et al., 2003).
Much attention of preventive medicine research is focused
on natural antioxidants. This interest refers not only to isola-
tion and identiﬁcation of new biologically active molecules
by the pharmaceutical industry, but also because of the emer-
gent public interest in using crude plant extracts (Dragland
et al., 2003).
L-carnitine (LC) is a vitamin-like substance that is structur-
ally similar to amino acids. Most carnitine is obtained from diet
such asmushroom, carrot, bread, rice and tomato. It can also be
synthesized endogenously by skeletalmuscle, heart, liver, kidney
and brain from the essential amino acids lysine and methionine
(Rebouche and Seim, 1998). It is known that LC and its deriva-
tives prevent the formation of reactive oxygen species (ROS) and
protect cells from per oxidative stress (Dokmeci et al., 2006).It is
generally accepted that exogenous carnitine, either at normal
dietary intake levels or in pharmacological amounts can be ben-
eﬁcial in a number of physiopathological conditions. The depen-
dence on carnitine uptake is evident frompatients suffering from
primary systemic carnitine deﬁciency (CDSP), an autosomal
recessive disorder of fatty acid oxidation, caused by mutations
in theOCTN2 gene encoding, an organic cation/carnitine trans-
porter (Wang et al., 1999). It has been reported that carnitine
protects the myocardium against ischemia (Reznick et al.,
1992), myocardial infarction (Singh et al., 1996) and skeletal
muscle myopathy in heart failure (Vescovo et al., 2002). Recent
reports have also suggested that carnitine has additional pleio-
tropic functions in tissues that are not considered lipogenic, such
as brain (Llansola and Felipo, 2002). Some studies indicate a
carnitine-dependent reduction of either DNA single-strand
breaks in isolated human lymphocytes after in vitro treatment
with an oxygen radical-generating system (Boerrigter et al.,
1993) or DNA cleavage induced by H2O2 UV-photolysis
(Vanella et al., 2000). Also, LC has DNA-repair capability and
decreased induction of aberrations in Ataxia telangiectasia (A-
T) patients (Berni et al., 2008).
Due to common industrial application of AA and its pres-
ence in food to ﬁnd an agent to decrease the cytotoxicity and
genotoxicity of AA is a good choice. The present study is
therefore aimed to investigating the possibility that LC may in-
hibit AA cytotoxicity and genotoxicity in somatic and germ
cells of the mice.2. Materials and methods
2.1. Animals
Male white Swiss mice aged 9–12 weeks were used in all
experiments. The animals were obtained from a closed ran-
dom-bred colony at the College of Pharmacy, University of
King Saud in Rhiyad. The mice used for any one experiment
were selected from mice of similar age (±1 week) and weight
(±2 g). Animals were housed in polycarbonate boxes with
steel-wire tops (not more than ﬁve animals per cage) and bed-
ded with wood shavings. Ambient temperature was con-
trolled at 22 ± 3 C with a relative humidity of 50 ± 15%
and a 12-h light/dark photoperiod. Food and water were pro-
vided ad libitum. Animals were sacriﬁced after treatment by
cervical dislocation.
2.2. Chemicals
L-carnitine is produced by Sigma-Tau Pharmaceuticals, Pome-
zia, Roma, Italy. Acrylamide was purchased from Sigma (St.
Louis, MO). All other chemicals used were of the highest ana-
lytical grade.
2.3. Treatment and cytological preparations
2.3.1. Micronucleus and chromosome aberrations
For the analysis of micronuclei and chromosome aberrations
in bone marrow cells, mice were orally treated (using a stom-
ach tube) with a single dose of AA at doses of 10, 20 and
30 mg/kg b.wt. Samples were taken 24 h after treatment. For
the repeated dose experiment, mice received daily oral doses
of 10 mg/kg b.wt. AA for 1 and 2 weeks (7 and 14 days). In
the repeated dose treatments, other groups of mice were given
100 and 200 mg LC, simultaneously with the AA. A negative –
non-treated – control group of mice was examined. In addi-
tion, other groups of mice were given the oral doses of LC
(100 and 200 mg/kg b.wt.) for 1 and 2 weeks.
2.4. Slide preparation and scoring
2.4.1. Micronucleus test
The micronucleus assay from mouse bone-marrow cells was
performed following the standard procedure described by Sch-
mid (1973). 5000 polychromatic erythrocytes (PCE) were
counted, ﬁve mice per treatment (1000 PCE per mouse) for
scoring MN. The signiﬁcance of the experimental data from
control data was calculated using differences between 2 pro-
portions (Daniel, 1974), in the case of PCE and the tables of
Kastenbaum and Bowman (1970) for micronuclei in polychro-
matic erythrocytes (MPCE).
2.4.2. Chromosome aberrations
Mice were injected i.p. with colchicine 2–3 h before sacriﬁce.
Bone marrow preparations were made according to the tech-
nique described by Yosida and Amano (1965). A group of ﬁve
mice was used for each treatment and 100 well-spread meta-
phases were analyzed per animal scoring for different kinds
of abnormalities including gaps, breaks, fragments, deletions,
Robertsonian translocations and polyploid metaphases.
Figure 1 Microphotograph shows polychromatic erythrocyte
with Micronuclei(black arrow) from mouse bone marrow cells
treated with acrylamide.
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Groups of ﬁve mice were orally treated with AA daily for ﬁve
consecutive days at dose levels of 10, 20 and 30 mg/kg b.wt.
Other groups of mice were given LC at 100 and 200 mg/
kg b.wt. together with the highest dose of AA. Animals were
sacriﬁced 35 days after the ﬁrst treatment by cervical disloca-
tion. Sperms from non-treated mice and from mice given only
LC at 100 and 200 mg/kg b.wt., daily for 5 days, were also
examined (control groups). Sperms were prepared according
to the recommended method of Wyrobek and Bruce (1978).
The epididymides were excised and minced in 2 ml physiolog-
ical saline, dispersed and ﬁltered to remove large tissue
fragments. Smears were prepared and stained with 1% Eosin
Y. A total of 1000 sperm were counted per animal, scoring dif-
ferent types of sperm abnormalities.
For chromosome aberrations and sperm shape abnormali-
ties data, the signiﬁcance of the difference between groups
and negative control was calculated using the t-test.
3. Results
3.1. Micronucleus test
From the results presented in Table 1 we found that the
percentage of micronucleated-polychromatic erythrocytes
(MPCE) increased signiﬁcantly by increasing the dose and time
of treatment of AA. The occurrence of MPCE was statistically
signiﬁcant after all the treatment compared to control group(-
except with single low dose). The protective effect of LC at 100
and 200 mg/kg b.wt. treated simultaneously with 10 mg AA/
kg b.wt. for 1 and 2 weeks reduced MPCE compared with
AA alone in dose-dependent manner (Table 1 and Fig. 1).Table 1 Frequency of polychromatic erythrocytes (PCE) with
micronuclei in mouse bone marrow cells after oral treatment
with different doses of acrylamide (AA) and AA with
L-carnitine (LC).
Treatment Doses
(mg/kg b.wt.)
No. of
MPCE
% MN
(PCE± SE)
Control –– 26 0.52 ± 0.39
Single AA 10 38 0.76 ± 0.46
20 58 1.16 ± 0.51*
30 71 1.42 ± 0.50**
Repeated 1 week LC 100 29 0.58 ± 0.62
200 27 0.54 ± 0.81
AA 10 156 3.12 ± 0.71**
AA+ LC 10 + 100 65 1.30 ± 0.63**
10 + 200 55 1.10 ± 0.40*
2 weeks LC 100 31 0.62 ± 0.50
200 33 0.66 ± 0.71
AA 10 217 4.34 ± 0.60**
AA+ LC 10 + 100 101 2.02 ± 0.54**
10 + 200 80 1.60 ± 0.42**
5000 PCE were counted, ﬁve mice per treatment (1000 PCE per
mouse).
* Signiﬁcant p< 0.05 level.
** Highly signiﬁcant p< 0.01 level.3.2. Chromosome aberrations
Table 2 and Fig. 2 present chromosome aberrations induced in
bone-marrow cells after single and repeated oral treatments,
with different doses of AA. The results show that the tested
doses of AA induced a statistically signiﬁcant increase in the
percentage of chromosome aberrations even after excluding
the gaps. Such percentage was found to be dose and time
dependent. The results in Table 2 also demonstrate that the
percentage of chromosome aberrations in bone marrow cells
was signiﬁcantly reduced in all groups of mice treated simulta-
neously with LC at 100 and 200 mg/kg b.wt. and with AA at
the tested dose levels.
3.3. Sperm-shape abnormalities
The effects of different doses of AA (10, 20 and 30 mg/
kg b.wt.) on the induction of sperm abnormalities in male mice
are summarized in Table 3. The results show that the three
tested doses of AA induced an increase in the percentage of
sperm abnormalities, with a positive dose response. This per-
centage reached a maximum of 7.24 ± 0.61 (P< 0.01) after
treatment with the highest test dose of AA compared with
1.52 ± 0.44 for the non-treated control. The results in Table 3
also show that LC signiﬁcantly reduced the AA-induced sperm
abnormalities. Various morphological sperm abnormalities in
heads and tails were observed (Fig. 3). Some heads may ac-
quire unusual shape; others show a reduced or increased size.
Coiled tail abnormalities were also recorded.
4. Discussion
The present study clearly conﬁrms the in vivo genotoxicity of
AA, which induced DNA damage in mouse bone marrow cells.
In fact, a single dose of AA at 10, 20 and 30 mg/kg b.wt. and
repeated dose with 10 mg/kg b.wt. for 1 and 2 weeks increases
the percentage of MN and chromosome aberrations value in
dose and time response. The observations conﬁrm the geno-
toxic capacity of AA as previously demonstrated by other
authors using other biomarkers as genetic damage criteria
(Knaap et al., 1988; Chiak and Vontorkva, 1988). Addition-
ally, the results are also in agreement with those obtained in
Table 2 Types of different chromosome aberrations induced in mouse bone – marrow cells after oral treatment with different doses of
acrylamide (AA) and AA with L-carnitine (LC).
Treatment Doses
(mg/kg b.wt.)
No. of abnormal cells Chromosome aberrations
No Including gap
(Mean %± SE)
Excluding gaps
(Mean %± SE)
Gaps Breaks and/
or Fragment
Deletion RT Polyploidy
Control –– 14 2.80 ± 0.60 1.60 ± 0.56 6 5 3 – –
Single AA 10 23 4.60 ± 0.64 2.80 ± 0.65 9 10 4 – –
20 32 6.40 ± 0.70** 3.40 ± 0.38* 15 13 4 – –
30 40 8.00 ± 0.50** 4.40 ± 0.52** 18 14 6 – 2
Repeated 1 week LC 100 15 3.00 ± 0.53 1.80 ± 0.57 6 6 3 – –
200 14 2.80 ± 0.68 1.20 ± 0.58 8 4 2 – –
AA 10 55 11.00 ± 0.60** 7.40 ± 0.50** 18 27 6 – 4
AA+ LC 10 + 100 42 8.40 ± 0.55** 5.20 ± 0.55** 16 21 5 – –
10 + 200 34 6.80 ± 0.58** 4.00 ± 0.50** 11 16 3 – 1
2 weeks LC 100 12 2.40 ± 0.52 1.20 ± 0.68 6 3 3 – –
200 14 2.80 ± 0.56 1.00 ± 0.50 9 3 2 – –
AA 10 69 13.80 ± 0.78** 10.00 ± 0.66** 19 33 8 2 7
AA+ LC 10 + 100 48 9.60 ± 0.52** 6.60 ± 0.60** 15 23 6 1 3
10 + 200 38 7.60 ± 0.58** 5.00 ± 0.50** 13 20 5 – –
500 metaphases examined in ﬁve mice per treatment. R.T. = Robertsonian translocation.
* Signiﬁcant p< 0.05 level.
** Highly signiﬁcant p< 0.01 level.
32 H.A.S. Alzahranithe Abramsson-Zetterberg’s study (2003) consisting of two
experiments with CBA mice, injected i.p. with different AA
doses. In one experiment, the effects of 22 doses ranging from
0 to 100 mg/kg b.wt. were studied. In the second experiment,
seven doses ranging from 0 to 30 mg/kg b.wt. were used. In
both experiments, a clear increase of the micronucleated-poly-
chromatic erythrocyte frequency was observed in dose-depen-
dent manner. Consumption of fried carbohydrate-rich food
containing AA causes an increased level of micronucleated
young erythrocytes in humans (Abramsson-Zetterberg et al.,
2008). Moreover, Adler et al. (1988) reported that i.p. treat-
ment with AA at doses 50–150 mg/kg b.wt. induced elevation
in micronuclei and chromosome aberrations in mice bone-mar-
row cells in dose-dependent manner. Also, many authors con-
ﬁrmed the ability of AA to induce chromosome aberrations
in vitro in Chinese hamster V79 cells (Oliveira et al., 2009)
and in vivo in mice bone marrow (Adler et al., 1988), lympho-
cyte (Backer et al., 1989) and splenocyte cells (Kligerman et al.,
1991).
The induction of sperm abnormalities by any agent is of
great signiﬁcance. It has the potential of allowing identiﬁcation
of chemicals that induce spermatogenic dysfunction and per-
haps heritable mutation (Wyrobek et al., 1983). In relation
to mutagenicity, sperm shape is reported to be genetically con-
trolled by numerous genes (Ito et al., 2004). The results showed
that AA induced signiﬁcant sperm abnormalities after treat-
ment of mice with different doses. Both head and tail abnor-
malities were recorded. The head abnormalities most
probably reﬂect a change in DNA content Wyrobek and Bruce
(1978). Coiling of sperm tail mainly involves its orientation,
which gives the impression of a reduced sperm movement.
Such limitation in sperm movement was reported to reduce fer-
tility in both animals and humans. For example, aberrations of
sperm tail – including coiled tails – were found in all cellsexamined from the semen of an infertile goat (Molnar et al.,
2001). Jouannet et al. (1988) found a strong relationship be-
tween human infertility and the number of abnormalities per
abnormal sperm, including head abnormalities and coiled tail.
Coiled tails were also recorded in about half of the spermato-
zoa tested from an infertile man (Baccetti et al., 1977).
The results are in the same line with the observations of
other authors recording the positive effect of AA and its
metabolite on the rodent germ cells. AA was reported to pro-
duce chromosome aberrations in mouse spermatogonia
(Shiraishi, 1978) and dominant-lethal mutations in spermato-
zoa and late spermatids of mice (Shelby et al., 1986). Adler
et al. (1994) observed a frequency of translocation carriers of
10/367 in offspring of males exposed i.p. to 100 mg AA/
kg b.wt. which resulted from conceptions 7–16 days post-treat-
ment (spermatid stage exposure). Generoso et al. (1996) re-
ported that exposed male mice to GA, an active metabolite
of AA, induced dominant-lethal mutations, heritable translo-
cations and unscheduled DNA synthesis in germ cells. Also,
the same authors found that a frequency of 135/669 transloca-
tion carriers in offspring from males exposed to 100 mg GA/
kg b.wt. and the F1 animals assayed were derived from con-
ceptions occurring 3.5–7.5 days post-treatment (spermatozoa
stage exposure), and the observed translocation frequency
was signiﬁcantly higher than in the AA treatment group
(P< 0.0001, Fisher’s exact test, two-tailed).
Wang et al. (2010) indicated that the epididymal sperm re-
serves decreased signiﬁcantly (P< 0.05), suggesting partial
depletion of germ cells. In addition, histopathological lesions
were also present in the testes of treated rats with acrylamide
at the doses 5 and 10 mg/kg/d for 8 consecutive weeks.
Epidemiologic evaluations of cancer risk in workers who
were exposed occupationally to AA were also undertaken.
Two cohorts of industrial workers who were exposed in the
Figure 2 Metaphases from mouse bone marrow cells treated with acrylamide showing: (A) normal, (B) break, (C) fragment, (D) gap,
(E) deletion and gap, (F) polyploidy.
Table 3 Types of different Sperm abnormalities induced in male mice after oral treatment with different doses of acrylamide (AA) and
AA with L-carnitine (LC).
Treatment Doses (mg/kg b.wt.) Abnormal sperm No. of sperm head abnormalities Coiled tail
No Mean %± SE Amorphous Without hook Triangle Banana Small Big
Control –– 76 1.52 ± 0.44 26 12 25 5 – – 8
LC 100 71 1.42 ± 0.50 22 10 26 6 – – 7
200 78 1.56 ± 0.45 30 11 28 5 – – 4
AA 10 196 3.92 ± 0.51** 43 25 71 8 3 3 43
20 266 5.32 ± 0.54** 57 37 99 17 7 5 44
30 362 7.24 ± 0.61** 100 62 102 20 8 4 66
AA+ LC 30+100 260 5.20 ± 0.51** 65 49 60 22 12 5 47
30+200 201 4.02 ± 0.58** 50 41 53 19 10 2 26
5000 sperm were counted, ﬁve mice per treatment (1000 sperm per mouse).
** Highly signiﬁcant p< 0.01 level.
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Figure 3 Sperm abnormalities induced in male mice orally
treated with acrylamide showing: (A) normal, (B) amorphous,
(C) triangular, (D) without hook, (E) banana (F) big head, (G)
small head and (H) coiled tail.
34 H.A.S. Alzahranimonomer production and polymerization industries were
established and cancer incidence in those workers was evalu-
ated (Collins et al., 1989). Several epidemiological studies pub-
lished during the period 2003–2007 show no positive
association between dietary intake of AA or selected AA-con-
taining foods and the increased risks for cancer (Schulz et al.,
2001; Mucci et al., 2003a). However, a recently published
study did ﬁnd a positive association between dietary AA intake
and an increased risk for certain types of cancer (uterus and
ovary) in post-menopausal women (Mucci et al., 2003b;
Hogervorst et al., 2007). AA therefore poses a potentially sig-
niﬁcant risk to human health.
There is a general agreement that the people’s diet, charac-
terized by an abundance of fruits and vegetables, contributes
to the prevention of various chronic degenerative diseases such
as cardiovascular diseases and cancer (Trichopoulou and
Lagiou, 1997). LC is a small essential endogenous compound
present in all mammalian species. Most carnitine is obtained
from diet such as mushroom, carrot, bread, rice and tomato
(Rebouche and Seim, 1998).
This study observed that the administration of LC with AA
reduced DNA damage in mouse somatic and germ cells. The
modulation of DNA repair by LC, as an alternative mecha-
nism to counteract AA-mediated clastogenicity, is supported
by many studies suggested that LC could help the cells torepair single-strand breaks (SSBs) induced in DNA (Boerrigter
et al., 1993) and to protect it from oxygen-free radicals (Vanel-
la et al., 2000). Other studies indicated LC-dependent reduc-
tion of DNA single-strand breaks after in vitro treatment
with an oxygen radical-generating system (H2O2), in isolated
human lymphocytes (Garcia et al., 2006). Santoro et al.
(2005) reported that LC has the ability to inhibit chromosomal
damage induced by H2O2 as an oxidative stress in CHO cells.
Pre-treatment of mice with LC 1 h before exposure to mag-
netic ﬁeld caused a signiﬁcant recovery of mice testes damage
induced by high magnetic ﬁeld (Ramadan et al., 2002). Berni
et al. (2008) demonstrated that the LC pre-treatment on oxida-
tive DNA damage (tert-butyl-hydroperoxide) produced an
enhancement of the rate and the extent of DNA repair in Atax-
ia telangiectasia (A-T) patient’s cell lines at an early recovery
time. Furthermore, a reduction of all types of chromosomal
aberrations was observed, both in A-T and in wild-type cell
lines.
By taking into account these overall observations and the
ﬁnding that carnitine attenuates and inhibits some side effects
of doxorubicin and cisplatin, two well-known chemotherapeu-
tic drugs inducing free-radical formation and oxidative dam-
age to mitochondria (Galli and Fratelli, 1993; Luo et al.,
1999 and Chang et al., 2002),we hypothesized that LC might
modulate DNA damage and cell proliferation.
It is difﬁcult to provide a complete explanation why treat-
ment with LC exerts its preventive action against DNA dam-
age induced by AA. The chemoprotective effect of LC may
be due to its ability to act as a free radical scavenger (Garcia
et al., 2006). So it captures reactive oxygen species (ROS) re-
leased from AA (Liping et al., 2007) and prevents it to induce
DNA damage. Also, LC has the ability to induce regulation in
GSH content (Ibrahim et al., 2007). Both AA and GA
induced a concentration- and time-dependent GSH depletion
(Krebayashi and Ohno, 2006). GSH plays an important role
in protecting against injuries by oxidants and reactive electro-
philes in several tissues and cell lines (Shan et al., 1990).
It is worth to mention that, with regard to the mechanism
by which AA induces genetic damage, it has been recently re-
ported that pre-treatment of AA with antioxidant compounds
such as N-tert-butyl-alpha-phenylnitrone (PBN), a spin trap,
as well as vitamins C and D (Blasiak et al., 2004); Aloysia tri-
phylla a perennial, bushy plant (Zamorano-Ponce et al., 2006)
and hydroxytyrosol (Zhang et al., 2009) decreased the DNA-
damaging effect of AA.
In view of the results obtained in the present study, edible
riches with LC may therefore merit further consideration as
an edible with the potential for a beneﬁcial application in the
chemoprevention of AA genotoxicity and, possibly, human
carcinogenesis. Also, future studies need to check the possibil-
ities whether LC can contribute to block the AA’s epoxidation
process (i.e., by inhibiting P450 enzyme).Reference
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